Cariprazine modulates sleep architecture in rats.

Area of Science:

• Neuroscience
• Pharmacology
• Sleep Medicine

Background:

• Cariprazine is a dopamine D3/D2 receptor partial agonist used for schizophrenia and bipolar disorder.
• Despite clinical classification as low-somnolence, no polysomnographic data exists on cariprazine's sleep effects.
• This study investigates cariprazine's impact on sleep architecture and EEG spectral power in rats.

Purpose of the Study:

• To examine the acute systemic effects of cariprazine on rat sleep architecture.
• To analyze cariprazine's impact on electroencephalography (EEG) spectral power during wakefulness and sleep.

Main Methods:

• Sprague Dawley rats underwent polysomnography for four hours.
• Sleep stages were classified, and EEG spectral power was analyzed.
• Cariprazine was administered intraperitoneally at doses of 0.3, 0.03, and 0.003 mg/kg.

Main Results:

• A dose of 0.3 mg/kg cariprazine reduced REM sleep and increased REM latency.
• This dose also decreased gamma band oscillations and increased theta and alpha frequencies during wakefulness.
• Lower doses showed minimal or no significant effects on sleep architecture or EEG power.

Conclusions:

• The REM-suppressing effect of cariprazine may link to its antidepressant properties.
• Reduced gamma power might indicate efficacy in schizophrenia or mania, similar to other receptor antagonists.
• These findings elucidate cariprazine's complex mechanism of action and clinical efficacy.